Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Feb;81(2):196-200.
doi: 10.1111/j.1349-7006.1990.tb02548.x.

Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D)

Y Sasaki  1 , M Fukuda, M Morita, T Shinkai, K Eguchi, T Tamura, Y Ohe, K Yamada, A Kojima, K Nakagawa, et al.
Affiliations

Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D)

Y Sasaki et al. Jpn J Cancer Res. 1990 Feb.

Abstract

Thrombocytopenia is the most serious dose-limiting toxicity of (glycolato-O,O')-diammine platinum (II) (254-S; NSC 375101D), one of the new platinum analogues. A total of 38 patients treated with 100 mg of 254-S per m2 in a clinical phase II study were retrospectively analyzed to determine the factors influencing thrombocytopenia. Performance status, sex, age and prior chemotherapy did not affect either the percent reduction of platelets or the nadir platelet count. However, creatinine clearance (Ccr.: ml/min) was found to be a predictive variable for thrombocytopenia. There was a significant relationship between nadir platelet count and Ccr. (R2 = 0.637) or relative dose [RD = (dose of 254-S: mg/m2)/Ccr.] (R2 = 0.707). From these observations, the following equations for predicting nadir platelet count associated with administration of 254-S were proposed. [Nadir platelet count] = -64,264.7 + 2,783.4 x [Ccr.] (A) log [Nadir platelet count] = -1.6743 log [RD] + 5.32 = -1.6743 log [Dose/Ccr.] + 5.32 (B) If we administer 100 mg of 254-S per m2 to a patient with Ccr. of less than 40.3 ml/min, thrombocytopenia of grade 3 or more according to the Eastern Cooperative Oncology Group (ECOG) criteria (less than 50,000/mm3) can be predicted from equation (A). In these patients, dose modification using equation (B) is recommended.

PubMed Disclaimer

References

    1. ) Bishop , J. F. , Raghavan , D. , Oliver , I. , Reece , P. , Morris , R. and Friedlander , M. L.A phase I study of trimetrexate (NSC 352122) administered by 5‐day continuous intravenous infusion . Cancer Chemother. Pharmacol. , 24 , 246 – 250 ( 1989. ). - PubMed
    1. ) Egorin , M. J. , van Echo , D. A. , Tipping , S. J. , Olman , E. A. , Whitacre , M. Y. , Thompson , B. W. and Aisner , J.Pharmacokinetics and dosage reduction of cis‐diammine‐(1,1‐cyclobutanedicarboxylato)platinum in patients with impaired renal function . Cancer Res. , 44 , 5432 – 5438 ( 1984. ). - PubMed
    1. ) Egorin , M. J. , van Echo , D. A. , Olman , E. A. , Whitacre , M. Y. , Forrest , A. and Aisner , J.Prospective validation of a pharmacologically based dosing scheme for the cis‐diamminedichloroplatinum (II) analog diamminecyclo‐butanedicarboxylatoplatinum . Cancer Res. , 45 , 6502 – 6506 ( 1985. ). - PubMed
    1. ) Egorin , M. , van Echo , D. A. , Whitacre , M. Y. , Forrest , A. , Sigman , L. M. , Engish , K. L. and Aisner , J.Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7‐OMEN, NSC 269148) and the correlation with clinical toxicities . Cancer Res. , 46 , 1513 – 1520 ( 1986. ). - PubMed
    1. ) Egorin , M. , Conley , B. A. , Forrest , A. , Zuhowski , E. G. , Sinibaldi , V. and Van Echo , D. A.Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction . Cancer Res. , 47 , 6104 – 6110 ( 1987. ). - PubMed

Publication types

LinkOut - more resources